| 药物基因检测指导个体化用药对首发精神分裂症患者的影响 |
| 投稿时间：2024-07-25 修订日期：2024-08-14 点此下载全文 |
| 引用本文：刘海港,李腾,赵蕊,韩荦杰,鲍晶晶,张晓娟,张顺.药物基因检测指导个体化用药对首发精神分裂症患者的影响[J].医学研究杂志,2025,54(1):97-101 |
| DOI：
10.11969/j.issn.1673-548X.2025.01.018 |
| 摘要点击次数: 93 |
| 全文下载次数: 81 |
|
| 基金项目:河北省医学科学研究课题计划项目(20241260) |
|
| 中文摘要:目的 探讨药物基因检测指导个体化用药对首发精神分裂症患者的影响。方法 选取2018年1月~2019年6月笔者医院收治的120例首发精神分裂症患者,按随机数字表法分为对照组(根据医师经验化药物治疗)和实验组(根据药物基因检测选择药物治疗),各60例。随访3年,对比两组患者病情变化、不良反应、治疗依从性、家庭及社会功能情况、生活质量。结果 实验组出院时、1年后、3年后阳性与阴性症状量表(positive and negative symptom scale,PANSS)总分低于对照组(t值分别为2.001、2.142、3.527,P值分别为0.048、0.034、0.001)。实验组出院时、1年后、3年后不良反应量表(adverse reaction scale,UKU)评分低于对照组(t值分别为2.914、3.473、3.429,P值分别为0.004、0.001、0.001),药物态度量表(drug attitude scale,DAI)评分高于对照组(t值分别为2.687、2.865、2.447,P值分别为0.008、0.005、0.016)。实验组出院时、1年后、3年后家庭功能量表(family function scale,FAD)评分高于对照组(t值分别为2.088、2.607、2.088,P值分别为0.039、0.010、0.039),社会功能缺陷筛选量表(social dysfunction screening scale,SDSS)评分低于对照组(t值分别为3.594、2.999、3.204,P值分别为<0.001、0.003、0.002)。实验组出院时、1年后、3年后精神分裂症生活质量量表(schizophrenia quality of life scale,SQLS)总分低于对照组(t值分别为2.754、2.523、2.493,P值分别为0.007、0.013、0.014)。结论 经3年随访研究结果表明,药物基因检测指导个体化用药可促进首发精神分裂症患者的病情改善,降低不良反应,提高治疗依从性,提高家庭、社会功能及生活质量。 |
| 中文关键词:精神分裂症 首发 药物基因检测 个体化用药 病情转归 |
| |
| Impact of Drug Gene Testing Guidance on Individualized Medication for First-episode Schizophrenia Patients. |
|
|
| Abstract:Objective To explore the impact of drug gene testing guidance on individualized medication for first-episode schizophrenics. Methods A total of 120 patients with first-episode schizophrenia received in our hospital were randomly divided into a control group (receiving drug treatment based on doctors′ experience) and experimental group (receiving treatment based on drug gene testing), with 60 patients in each group. After 3 years of following-up, the changes in condition, adverse reactions, treatment compliance, family and social functions, and quality of life of the two groups of patients were compared. Results When discharged from the hospital, 1 year and 3 years later, the total score of the positive and negative symptom scale (PANSS) in the experimental group was lower than that in the control group (t were 2.001,2.142,3.527； P were 0.048,0.034,0.001); the scores of adverse reaction scale (UKU) in the experimental group were lower (t were 2.914,3.473,3.429； P were 0.004,0.001,0.001), and the scores of drug attitude scale (DAI) were higher than those in the control group (t were 2.687,2.865,2.447； P were 0.008,0.005,0.016); the scores of family function scale (FAD) in the experimental group were higher (t were 2.088, 2.607, 2.088； P were 0.039,0.010,0.039), and the scores of social dysfunction screening scale (SDSS) were lower (t were 3.594, 2.999, 3.204； P were <0.001,0.003,0.002). The total score of schizophrenia quality of life scale (SQLS) in the experimental group was lower than that in the control group (t were 2.754,2.523, 2.493； P were 0.007,0.013,0.014). Conclusion After three years of follow-up, the results show that drug gene testing can promote the prognosis of first-episode schizophrenia patients, reduce adverse reactions, improve treatment compliance, and enhance the functions of family and society and quality of life. |
| keywords:Schizophrenia Starting Drug gene testing Individualized medication The prognosis of the disease |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
